Go to main content

Antibody-drug conjugates [electronic resource] : the 21st century magic bullets for cancer / Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro, editors.

Wang, Jeffrey, editor.; Shen, Wei-Chiang, 1942- editor.; Zaro, Jennica L., editor.
2015
RS201.A56 A58 2015eb
Available Online
Formats
Format
BibTeX
MARCXML
TextMARC
MARC
DublinCore
EndNote
NLM
RefWorks
RIS
Add to Basket
Cite
Citation

Linked e-resources

Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks

Details

Title
Antibody-drug conjugates [electronic resource] : the 21st century magic bullets for cancer / Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro, editors.
ISBN
9783319130811 electronic book
3319130811 electronic book
9783319130804
DOI
https://doi.org/10.1007/978-3-319-13081-1
Published
Cham : Springer, [2015]
Copyright
©2015
Language
English
Description
1 online resource (x, 252 pages) : illustrations.
Item Number
10.1007/978-3-319-13081-1 doi
Call Number
RS201.A56 A58 2015eb
Dewey Decimal Classification
615.3/7
Summary
This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
Note
Includes index.
Bibliography, etc. Note
Includes bibliographical references and index at the end of each chapters.
Access Note
Access limited to authorized users.
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed March 11, 2015).
Added Author
Wang, Jeffrey, editor.
Shen, Wei-Chiang, 1942- editor.
Zaro, Jennica L., editor.
Series
AAPS advances in the pharmaceutical sciences series ; volume 17.
Available in Other Form
Print version: 9783319130804
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
1 Antibody-Drug Conjugates: A Historical Review
2 Payloads of Antibody-Drug Conjugates
3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy
4 Linker Design for Antibody-Drug Conjugates
5 Formulation Development for Antibody-Drug Conjugates
6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates
7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates
8 Regulatory Considerations
9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy
10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal
11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate
12 Ado-Trastuzumab Emtansine
13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer
14 Summary and Future Directions.

Browse Subjects

Show more subjects...

Statistics

from
to
Export